Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What's Missing In Intellipharmaceutics' Opioid Filing? FDA Panel Offers List

Jul 30 2017

• By Brenda Sandburg

Prescription Opiate and Heroin Abuse

Related Content

Abuse Deterrent Opioids: Which Studies Will Show Real World Effect?

Jul 20 2017

New Opioids: FDA Should Ditch 'Product-Specific Approach,' Science Report Says

Jul 14 2017

FDA Panel Rejects Intellipharmaceutics' Opioid For Missing Data, Blue Dye Safety Concern

Jul 27 2017

Related Companies

Intellipharmaceutics International Inc.

Merck & Co., Inc.

Additional Topics

United States Advisory Committees Drug Safety Drug Review Regulation Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window